Dose-response relationships of propranolol in Chinese subjects with different CYP2D6 genotypes

Journal of the Chinese Medical Association

Volumn 66, Issue 1, 2003, Pages 57-62

  Huang, Chin Wei ^a   Lai, Ming Liang ^a   Lin, Min Shung ^b   Lee, Hwei Ling ^a   Huang, Jin Ding ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CATHAY GENERAL HOSPITAL   (Taiwan)

Author keywords

Cytochrome P450 2D6; Debrisoquine; Genetic polymorphism; Propranolol

Indexed keywords

CYSTEINE; CYTOCHROME P450 2D6; NUCLEOTIDE; PROPRANOLOL; THREONINE; CYP2C19 PROTEIN, HUMAN; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE MEASUREMENT; CHINESE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG METABOLISM; ENZYME POLYMORPHISM; GENOTYPE; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYPOTHESIS; MALE; NORMAL HUMAN; STANDING; SUPINE POSITION; TABLET FORMULATION; TIME; TREADMILL EXERCISE; BLOOD PRESSURE; DRUG EFFECT; GENETIC POLYMORPHISM; GENETICS;

ARYL HYDROCARBON HYDROXYLASES; BLOOD PRESSURE; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HEART RATE; HUMANS; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; PROPRANOLOL;

EID: 0037981622     PISSN: 17264901     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Raghuram TC, Koshakji RP, Wilkinson GR, Wood AJ. Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels but not beta blockade. Clin Pharmacol Ther 1984;36:51-6.
2. Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA. Propranolol metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther 1989;45:72-9.
3. Lermard MS, Jackson PR, Freestone S, Tucker GT, Ramsay LE, Woods HF. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. Br J Clin Pharmacol 1984;17:679-85.
4. Lai ML, Wang SL, Lai MD, Lin ET, Tse M, Huang JD. Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1995;58:264-8.
5. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993;53:410-8.
6. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989; 45:889-904.
7. Tseng CY, Wang SL, Lai MD, Lai ML, Huang JD. Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1996;60:177-82.
8. Armstrong M, Fairbrother K, Idle JR, Daly AK. The cytochrome-P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics 1994;4:73-81.
9. Zhou HH, Koshakji RP, Silberstein DJ, Wilkinson GR, Wood AJ. Racial differences in drug response: altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl J Med 1989; 320:565-70.
10. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996;6:193-201.
11. 1934 →A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am J Hum Genet 1990;47:994-1001.
12. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
13. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin in Japanese. Mol Pharmacol 1994;46:594-8.
14. Johansson I, Lundqvist E, Dahl ML, Ingelman-Sundberg M. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 1996;6:351-5.
15. Wang SL, Lai MD, Huang JD. G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese. Drug Metab Dispos 1999;27:385-8.
16. Wu ST, Chang YP, Gee WL, Benet LZ, Lin ET. Stereoselective high-performance liquid chromatography determination of propranolol and 4-hydroxypropranolol in human plasma after precolumn derivation. J Chromatogr B 1997;692:133-40.
17. Fitzgerald JD, O'Donnell SR. Pharmacology of 4-hydroxypropranolol, a metabolite of propranolol. Br J Pharmacol 1971;43:222-35.